Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

MED Binding Joint Venture Completion Update

4 Aug 2023 07:00

RNS Number : 2703I
Mast Energy Developments PLC
04 August 2023
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

('MED' or 'the Company')

 

Dated: 4 August 2023

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

MED Binding Joint Venture Completion Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, announces that further to its previous announcement dated 12 July 2023, it has extended the completion long-stop date for the first definitive and binding Joint Venture Agreement ('JVA') on account of exceptional circumstances. The revised completion date is now expected around 31 August 2023. The extension is due to the principal of Seira Capital, MED's JV lead investor partner, who was involved in a tragic road accident in which he was seriously injured and is still hospitalised and in critical condition. MED is currently working with the JV investor consortium to expedite the transfer of the JVA investment funds and to complete the transaction without any further undue delay. In this regard, the Company has received the full co-operation of the investor consortium and has already reached agreement on how the revised completion long-stop date can be met. The parties are now working on finalising the necessary logistical and statutory arrangements to ensure successful completion and transfer of funds in accordance with the revised long-stop date.

 

Further, the JVA also commits both parties, as set out in MED's announcement dated 12 July 2023, to promptly finalise terms on a second joint venture that will increase the envisaged total investment value to c. £31m, with a total portfolio of low-carbon flexible gas generation peaker plants totally a combined generation output of up to c. 33  MW, to be developed and/or acquired, constructed and in production and income-generating under the two joint ventures ('Secondary JVA'). MED has now received the published guidance from the FCA and the FCA have confirmed that they agree with MED that entrance into the second joint venture would not constitute a reverse takeover. As such, notwithstanding the extension of completion of the first JVA as referred to above, MED will endeavour to finalise terms for the second JV promptly.

 

Pieter Krügel, CEO of MED, commented: "We wish our JV investor partner principal and his family all the best during this challenging time. We are pleased to receive support from the JV investor consortium in the meantime, and we are confident that we will be able to complete the transaction shortly.

"Further, we are pleased to have received the clearance from the FCA regarding the Secondary JVA, and we are looking forward to finalising the second JVA promptly and will update the market on both matters in due course."

 

ENDS

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

 

Pieter Krügel

Info@med.energy

Mast Energy

Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor & Media Relations Advisor

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSDFIDEDSELA
Date   Source Headline
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn
20th Dec 20222:00 pmRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSPyebridge SPA Deferred Consideration Settlement
15th Dec 20222:00 pmRNSTR-1: Notification of major holdings
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSBordesley Update
17th Nov 20227:00 amRNSCorporate Presentation
3rd Nov 20227:00 amRNSFurther Funding Secured
31st Oct 20221:41 pmRNSClarification of Pyebridge Trading Update
27th Oct 20224:41 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20222:05 pmRNSSecond Price Monitoring Extn
24th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 202211:05 amRNSSecond Price Monitoring Extn
24th Oct 202211:00 amRNSPrice Monitoring Extension
24th Oct 20229:05 amRNSSecond Price Monitoring Extn
24th Oct 20229:00 amRNSPrice Monitoring Extension
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
21st Oct 20222:06 pmRNSSecond Price Monitoring Extn
21st Oct 20222:00 pmRNSPrice Monitoring Extension
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
20th Oct 20224:41 pmRNSSecond Price Monitoring Extn
20th Oct 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.